stockrow
Saturday 7 November 2026
Export BRTX’s income statement to Excel — free account
Biorestorative Therapies, Inc.
BRTX Healthcare Biotechnology
Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024.
- Revenue
- −7.20%
- EPS
- +81.3%
- Free cash flow
- −35.3%
Quarter to March 2026, against a year earlier
1.48
0.03
−1.99%
Follow BRTX
Alert me
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
24.05 | 34.48 | 29.38 | 13.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.40) | (4.56) | (4.38) | (1.27) | |
P/B ratio |
3.01 | 6.03 | 30.83 | 1.59 | |
Price to Tangible BV |
3.42 | 8.08 | 0.00 | 1.92 | |
EV/Sales |
12.17 | 23.26 | 21.70 | 3.97 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.77) | (0.83) | (0.72) | (0.12) | |
EV/FCF |
(0.68) | (0.75) | (0.65) | (0.11) | |
Quick Ratio |
2.01 | 1.31 | 0.80 | 2.23 | |
Current Ratio |
2.07 | 1.37 | 0.84 | 2.35 | |
Net Debt/EBITDA |
2.27 | 1.23 | 0.78 | 1.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.04 | 0.04 | 0.05 | |
Operating CF/Net income |
1.01 | 0.95 | 0.75 | 1.77 | |
Capex/Depreciation |
0.00 | 0.00 | (1.51) | 0.00 | |
Interest Coverage |
44.73 | — | 41.72 | 615.58 | |
Research and Development Expense of Revenue |
733.89% | 21,989.83% | 13,403.57% | 8,303.02% | |
Selling, General and Administrative Expense of Revenue |
453.02% | 9,453.39% | 6,204.59% | 6,358.62% | |
Intangible Assets out of Total Assets |
0.07 | 0.10 | 0.13 | 0.11 | |
Share Based Compensation of Revenue |
154.53% | 3,389.83% | 2,284.69% | 1,250.86% | |
Graham Net Nets |
0.27 | 0.10 | (0.06) | 0.45 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(76.25%) | (101.38%) | (135.32%) | (393.38%) | |
Free Cash Flow Yield |
(74.21%) | (90.37%) | (114.31%) | (271.86%) | |
Revenue per Share |
0.69 | 0.03 | 0.04 | 0.03 | |
Operating CF per Share |
(6.16) | (6.36) | (5.37) | (4.30) | |
Capex per Share |
0.00 | 0.00 | (0.18) | 0.00 | |
Free Cash Flow per Share |
(6.16) | (6.36) | (5.55) | (4.30) | |
Cash per Share |
16.89 | 9.85 | 6.57 | 4.05 | |
Shareholders Equity per Share |
11.09 | 4.84 | 0.79 | 3.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.09 | 4.84 | 0.79 | 3.41 | |
Free Cash Flow |
(2.69) | (2.90) | (2.49) | (3.81) | |
Working Capital |
3.93 | 1.27 | (0.59) | 2.19 | |
Capital Expenditures |
0.00 | 0.00 | (0.08) | — | |
Net Current Asset Value |
3.93 | 1.27 | (0.59) | 2.19 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 4.07 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.09 | 0.10 | 0.02 | |
Average Payables |
0.41 | 0.63 | 0.91 | 0.63 | |
Average Assets |
12.32 | 10.11 | 8.18 | 7.48 | |
Average Common Equity |
7.81 | 6.09 | 4.43 | 4.58 |
Columns are period end dates · fundamentals updated 26 Oct 2026